Skip to main content
Oncopeptides logo

Oncopeptides — Investor Relations & Filings

Ticker · ONCO ISIN · SE0009414576 LEI · 549300J9WWQ5CBYQ1M77 ST Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2024-11-22 Board/Management Inform…
Country SE Sweden
Listing ST ONCO

About Oncopeptides

https://www.oncopeptides.com/en

Oncopeptides is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company concentrates on hematological diseases, with a primary focus on multiple myeloma. Its commercialized product is Pepaxti (melflufen), a peptide-drug conjugate for adult patients with relapsed or refractory multiple myeloma. Founded in 2000 based on research from leading cancer institutions, Oncopeptides leverages its proprietary technology platforms to advance a pipeline of innovative drug candidates. The company's research also includes the development of Natural Killer (NK) cell engagers to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
Oncopeptides har utsett valberedningen
Board/Management Information Classification · 1% confidence The document is a short announcement from Oncopeptides AB dated November 22, 2024, stating that the Nomination Committee (valberedningen) for the upcoming Annual General Meeting (AGM) in 2025 has been established. It lists the members appointed by major shareholders and the chairman. The key focus is the composition and process related to the nomination committee for the AGM. This type of announcement, dealing with the composition of the board/management structure related to shareholder meetings, aligns most closely with Board/Management Information (MANG) or potentially Governance Information (CGR). However, since it specifically deals with the composition of the committee responsible for nominating board members for the AGM, it falls under the scope of management/governance structure changes. Given the options, MANG (Board/Management Information) is the most appropriate fit as it concerns the composition of a key governance body (the nomination committee) that precedes board appointments. It is not a full AGM presentation (AGM-R), nor is it a proxy solicitation (PSI) or a declaration of voting results (DVA). It is a specific announcement about the composition of a pre-AGM body.
2024-11-22 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 1% confidence The document is titled 'DELÅRSRAPPORT, Q3 2024' (Interim Report, Q3 2024) for the company Oncopeptides. It contains comprehensive financial data, including income statements, cash flow summaries, and management commentary on business performance for the period of July-September 2024. It is a substantive financial report rather than a mere announcement or certification, fitting the definition of an Interim/Quarterly Report. Q3 2024
2024-11-07 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 1% confidence The document is a quarterly financial report for Oncopeptides, covering the period of July-September (Q3). It contains detailed financial statements, including net sales, operating profit, earnings per share, and cash flow, as well as a CEO statement and detailed breakdowns of revenue, gross profit, and operating expenses. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q3 2024
2024-11-07 English
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 1% confidence The document is a 'Delårsrapport' (Interim Report) for Oncopeptides for the period April-June 2024. It contains comprehensive financial statements (income statement, cash flow, balance sheet notes), management commentary on business performance, and operational highlights. It is not a mere announcement (RPA) as it contains full financial data and analysis for the specified period. Q2 2024
2024-08-14 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 1% confidence The document is explicitly titled 'INTERIM REPORT, Q2 2024' and contains comprehensive financial statements, including a consolidated statement of comprehensive income, balance sheet data, and management's discussion and analysis of the financial results for the period ending June 30, 2024. It provides substantive financial data and analysis, fitting the definition of an Interim/Quarterly Report (IR). Q2 2024
2024-08-14 English
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document details a change in shareholding where Nordnet AB (publ) sold shares in Oncopeptides AB, resulting in their total holding dropping to 4.932% of voting rights. The structure, use of terms like 'Major shareholding notification', 'Shares', 'Voting rights', and the reporting of specific percentages and transaction dates (10/07/2024) are characteristic of filings mandated when an investor crosses a significant ownership threshold. This directly corresponds to the definition of Major Shareholding Notification.
2024-07-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.